{"id":"sinemet-plus","safety":{"commonSideEffects":[{"rate":null,"effect":"Dyskinesia"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Orthostatic hypotension"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL780","moleculeType":"Small molecule","molecularWeight":"393.35"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Levodopa crosses the blood-brain barrier and is converted to dopamine, replacing depleted dopamine in Parkinson's patients. Carbidopa inhibits peripheral conversion of levodopa to dopamine, allowing more levodopa to reach the brain. Entacapone inhibits catechol-O-methyltransferase (COMT), an enzyme that breaks down dopamine, thereby extending dopamine's duration of action and reducing motor fluctuations.","oneSentence":"Sinemet Plus combines levodopa (a dopamine precursor) with carbidopa (a decarboxylase inhibitor) and entacapone (a COMT inhibitor) to increase dopamine availability in the brain for Parkinson's disease treatment.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:08:11.808Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Parkinson's disease with motor fluctuations"}]},"trialDetails":[{"nctId":"NCT05781711","phase":"PHASE2","title":"Clinical Study to Evaluate the Possible Efficacy of Metformin in Patients With Parkinson's Disease","status":"COMPLETED","sponsor":"Tanta University","startDate":"2023-01-06","conditions":"Parkinson Disease","enrollment":60},{"nctId":"NCT06113640","phase":"PHASE2, PHASE3","title":"Montelukast in Parkinson Disease","status":"RECRUITING","sponsor":"Mostafa Bahaa","startDate":"2023-11-05","conditions":"Parkinson Disease","enrollment":60},{"nctId":"NCT04469959","phase":"PHASE2","title":"Dopaminergic Dysfunction in Late-Life Depression","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2021-02-15","conditions":"Late Life Depression, Cognitive Decline, Depressive Disorder, Treatment-Resistant","enrollment":100},{"nctId":"NCT06075771","phase":"PHASE4","title":"Dopaminergic Therapy for Anhedonia - 2","status":"RECRUITING","sponsor":"Emory University","startDate":"2023-11-21","conditions":"Anhedonia, Depression","enrollment":70},{"nctId":"NCT05043103","phase":"","title":"Long-Term Observational Study on Effectiveness and Safety of Lecigon in Patients With Advanced Parkinson's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Britannia Pharmaceuticals Ltd.","startDate":"2021-07-06","conditions":"Advanced Parkinson Disease","enrollment":312},{"nctId":"NCT06785298","phase":"PHASE2, PHASE3","title":"Fexofenadine as Adjuvant Therapy in Parkinson Disease","status":"RECRUITING","sponsor":"Tanta University","startDate":"2024-12-10","conditions":"Parkinson Disease","enrollment":46},{"nctId":"NCT06587217","phase":"PHASE1, PHASE2","title":"Neurobiological Drivers of Mobility Resilience: The Dopaminergic System - Supplemental Open-Label Arm","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2024-10-29","conditions":"Parkinsonian Signs in Older Persons","enrollment":5},{"nctId":"NCT07229664","phase":"PHASE2, PHASE3","title":"Vinpocetine in Patients With Parkinsonian Disease","status":"RECRUITING","sponsor":"Tanta University","startDate":"2025-11-10","conditions":"Parkinson Disease","enrollment":60},{"nctId":"NCT05708274","phase":"PHASE1","title":"Pharmacological Agents for Chronic Spinal Cord Injury (SCI)","status":"COMPLETED","sponsor":"Bronx VA Medical Center","startDate":"2023-01-20","conditions":"Spinal Cord Injuries","enrollment":25},{"nctId":"NCT07246278","phase":"PHASE1, PHASE2","title":"Celecoxib in Parkinson Disease as Adjuvant Therapy","status":"RECRUITING","sponsor":"Tanta University","startDate":"2025-11-20","conditions":"Parkinson Disease","enrollment":80},{"nctId":"NCT07229651","phase":"PHASE2, PHASE3","title":"Metformin in Parkinson Disease","status":"RECRUITING","sponsor":"Tanta University","startDate":"2025-11-10","conditions":"Parkinson Disease","enrollment":60},{"nctId":"NCT03022318","phase":"PHASE2","title":"Carbidopa-levodopa in Neovascular AMD","status":"COMPLETED","sponsor":"Snyder, Robert W., M.D., Ph.D., P.C.","startDate":"2017-05-02","conditions":"Age-related Macular Degeneration","enrollment":20},{"nctId":"NCT03023059","phase":"PHASE2","title":"Dose Ranging Study of Carbidopa-levodopa","status":"COMPLETED","sponsor":"Snyder, Robert W., M.D., Ph.D., P.C.","startDate":"2017-05-02","conditions":"Age-related Macular Degeneration","enrollment":35},{"nctId":"NCT07001150","phase":"PHASE2","title":"Role of Silymarin in Neuroprotection and Symptom Management in Parkinson's Disease","status":"RECRUITING","sponsor":"Tanta University","startDate":"2025-05-10","conditions":"Parkinson Disease","enrollment":50},{"nctId":"NCT04750226","phase":"PHASE3","title":"Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2021-02-18","conditions":"Parkinson's Disease (PD)","enrollment":118},{"nctId":"NCT05962957","phase":"PHASE2","title":"Role of Pentoxifylline and Celecoxib in Parkinsonism","status":"COMPLETED","sponsor":"Mostafa Bahaa","startDate":"2023-08-07","conditions":"Parkinson Disease","enrollment":80},{"nctId":"NCT04379050","phase":"PHASE3","title":"Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2020-06-08","conditions":"Parkinson's Disease (PD)","enrollment":130},{"nctId":"NCT04821830","phase":"PHASE4","title":"Vigor and the LDR in Parkinson Disease","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2020-02-12","conditions":"Parkinson Disease","enrollment":19},{"nctId":"NCT06219915","phase":"PHASE1, PHASE2","title":"Neurobiological Drivers of Mobility Resilience: The Dopaminergic System - Placebo-Controlled Arm","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2024-03-15","conditions":"Parkinsonian Signs in Older Persons","enrollment":13},{"nctId":"NCT02994719","phase":"","title":"Gait Analysis in Neurological Disease","status":"RECRUITING","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2016-03-01","conditions":"Parkinson's Disease, Parkinsonian Disorders, Atypical Parkinson Disease","enrollment":120},{"nctId":"NCT02726386","phase":"PHASE2","title":"A Long Term Safety Study of ND0612 Administered as a Continuous SC Infusion in Advanced Parkinson's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"NeuroDerm Ltd.","startDate":"2016-05-04","conditions":"Parkinson's Disease","enrollment":214},{"nctId":"NCT04006210","phase":"PHASE3","title":"Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations","status":"ACTIVE_NOT_RECRUITING","sponsor":"NeuroDerm Ltd.","startDate":"2019-09-30","conditions":"Parkinson's Disease","enrollment":381},{"nctId":"NCT06596876","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of HRG2010 in Parkinson's Disease With Motor Fluctuations","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2024-11-06","conditions":"Parkinson's Disease","enrollment":450},{"nctId":"NCT05369533","phase":"PHASE1, PHASE2","title":"Dopaminergic Enhancement of Rehabilitation Therapy Early After Stroke","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2022-08-01","conditions":"Stroke","enrollment":25},{"nctId":"NCT06432309","phase":"NA","title":"Opicapone as Adjunctive Therapy to Levodopa-Carbidopa Intestinal Gel in Parkinson's Disease","status":"COMPLETED","sponsor":"University Hospital of Ferrara","startDate":"2022-07-01","conditions":"Parkinson Disease, Effect of Drug","enrollment":22},{"nctId":"NCT04723147","phase":"PHASE4","title":"DTA (Dopaminergic Therapy for Anhedonia) Study","status":"COMPLETED","sponsor":"Emory University","startDate":"2021-01-29","conditions":"Depression, Anhedonia","enrollment":19},{"nctId":"NCT05463367","phase":"PHASE2","title":"Project 1 Aim 2, Adaptations of the Brain in Chronic Pain With Opioid Exposure","status":"ACTIVE_NOT_RECRUITING","sponsor":"Northwestern University","startDate":"2021-01-01","conditions":"Opioid Use, Opioid Dependence, Opioid-use Disorder","enrollment":60},{"nctId":"NCT03735901","phase":"PHASE3","title":"Enhancement of Stroke Rehabilitation With Levodopa","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2019-06-14","conditions":"Acute Stroke, Stroke Rehabilitation","enrollment":610},{"nctId":"NCT06614153","phase":"PHASE2","title":"Pharmacokinetics,Pharmacodynamics,Efficacy and Safety of HRG2010 in Parkinson's Disease Patients With Motor Fluctuations","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2023-05-16","conditions":"Parkinson's Disease","enrollment":61},{"nctId":"NCT02096601","phase":"PHASE1","title":"A Safety, Tolerability, and Pharmacokinetic Study of ND0612 Delivered as a Continuous Subcutaneous in Parkinson's Disease Patients","status":"COMPLETED","sponsor":"NeuroDerm Ltd.","startDate":"2014-08-11","conditions":"Parkinson's Disease","enrollment":16},{"nctId":"NCT00456794","phase":"PHASE2","title":"12-Week, Double-Blind, Placebo-Controlled Study of 20 and 60 mg/Day Istradefylline in Parkinson's Disease Patients on Levodopa/Carbodopa","status":"COMPLETED","sponsor":"Kyowa Kirin, Inc.","startDate":"2002-03","conditions":"Parkinson's Disease","enrollment":325},{"nctId":"NCT00199420","phase":"PHASE3","title":"A Study of Istradefylline (KW-6002) in Treating Patients With Parkinson's Disease on Levodopa","status":"COMPLETED","sponsor":"Kyowa Kirin, Inc.","startDate":"2004-07","conditions":"Parkinson's Disease","enrollment":580},{"nctId":"NCT00955045","phase":"PHASE2, PHASE3","title":"A Long-Term, Safety Study With a Flexible Dose Range of KW-6002 in Patients With Motor Response Complications on Levodopa/Carbidopa Therapy","status":"COMPLETED","sponsor":"Kyowa Kirin, Inc.","startDate":"2002-08","conditions":"Parkinson's Disease","enrollment":""},{"nctId":"NCT00456586","phase":"PHASE2","title":"12-Week, Double-Blind, Placebo-Controlled, Randomized Study of the Efficacy of 40 mg/Day KW-6002 in Parkinson's Disease Patients on Levodopa/Carbidopa","status":"COMPLETED","sponsor":"Kyowa Kirin, Inc.","startDate":"2002-04","conditions":"Parkinson's Disease","enrollment":180},{"nctId":"NCT03451500","phase":"PHASE2","title":"Carbidopa-Levodopa in Dry AMD With Geographic Atrophy","status":"TERMINATED","sponsor":"Snyder, Robert W., M.D., Ph.D., P.C.","startDate":"2018-07-01","conditions":"Age Related Macular Degeneration","enrollment":7},{"nctId":"NCT00199407","phase":"PHASE3","title":"A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa","status":"COMPLETED","sponsor":"Kyowa Kirin, Inc.","startDate":"2004-06","conditions":"Parkinson's Disease","enrollment":230},{"nctId":"NCT02763137","phase":"PHASE2","title":"Intermittent Oral Administration vs. Semi-continuous Intra-oral Administration of Levodopa/Carbidopa in Fluctuating Parkinsonian Patients","status":"COMPLETED","sponsor":"IRCCS San Raffaele Roma","startDate":"2014-07-30","conditions":"Parkinson Disease","enrollment":18},{"nctId":"NCT05087914","phase":"PHASE2","title":"Novel Non-opioid Post-surgical Pain Treatment in Females","status":"WITHDRAWN","sponsor":"Northwestern University","startDate":"2021-11-01","conditions":"Acute Pain, Bunionectomy, Toe Fusion","enrollment":""},{"nctId":"NCT06236230","phase":"PHASE4","title":"Basic and Clinical Studies of Levodopa/Carbidopa/Entacapone in the Treatment of Early Parkinson's Disease","status":"UNKNOWN","sponsor":"Second Affiliated Hospital of Soochow University","startDate":"2023-11-15","conditions":"Parkinson Disease","enrollment":60},{"nctId":"NCT02604914","phase":"PHASE1","title":"A Sequential Two-Part, Open-Label Study in Healthy Male and Female Subjects","status":"COMPLETED","sponsor":"NeuroDerm Ltd.","startDate":"2015-05-29","conditions":"Parkinson's Disease","enrollment":36},{"nctId":"NCT01883505","phase":"PHASE2","title":"A Phase 2a Study Followed to Evaluate the Safety, Tolerability and Levodopa Pharmacokinetics in Levodopa-treated Parkinson's Disease Patients Receiving ND0612","status":"COMPLETED","sponsor":"NeuroDerm Ltd.","startDate":"2014-01-06","conditions":"Parkinson's Disease","enrollment":30},{"nctId":"NCT03000569","phase":"PHASE2","title":"A Study to Evaluate SAGE-217 in Participants With Parkinson's Disease","status":"COMPLETED","sponsor":"Biogen","startDate":"2016-11-30","conditions":"Parkinson Disease","enrollment":29},{"nctId":"NCT02549092","phase":"PHASE3","title":"A Study to Examine the Effect of Levodopa-Carbidopa Intestinal Gel (LCIG) Therapy Relative to That of Optimized Medical Treatment (OMT) on Non-motor Symptoms (NMS) Associated With Advanced Parkinson's Disease (PD)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-10-26","conditions":"Advanced Parkinson's Disease","enrollment":89},{"nctId":"NCT03781167","phase":"PHASE3","title":"A Study to Evaluate the Safety and Tolerability of ABBV-951 in Subjects With Parkinson's Disease (PD)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2019-04-29","conditions":"Parkinson's Disease (PD)","enrollment":244},{"nctId":"NCT04052776","phase":"PHASE1","title":"Acute Effects of Pharmacological Neuromodulation on Leg Motor Activity in Patients With SCI Treated With EES","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire Vaudois","startDate":"2020-09-11","conditions":"Spinal Cord Injuries, Drug Effect","enrollment":3},{"nctId":"NCT02549573","phase":"PHASE4","title":"Outpatient Physical Therapy Intervention in Subjects With Parkinson's Disease Currently Using APOKYN®","status":"TERMINATED","sponsor":"MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals","startDate":"2016-01","conditions":"Parkinson's Disease, Motor Symptoms","enrollment":13},{"nctId":"NCT01770145","phase":"PHASE4","title":"Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT)","status":"COMPLETED","sponsor":"MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals","startDate":"2012-12","conditions":"Parkinson's Disease, Motor Symptoms, Akinesia","enrollment":127},{"nctId":"NCT03944785","phase":"","title":"Clinical Outcome Assessment of Parkinson's Disease Patients Treated With XADAGO (Safinamide)","status":"COMPLETED","sponsor":"Supernus Pharmaceuticals, Inc.","startDate":"2017-11-30","conditions":"Idiopathic Parkinson Disease","enrollment":164},{"nctId":"NCT02577523","phase":"PHASE2","title":"A Clinical Study of Efficacy, Safety, Tolerability and PK of ND0612H in Subjects With Advanced Parkinson's Disease","status":"COMPLETED","sponsor":"NeuroDerm Ltd.","startDate":"2015-12-29","conditions":"Parkinson's Disease","enrollment":38},{"nctId":"NCT03761030","phase":"PHASE4","title":"L-DOPA vs. Placebo for Depression and Psychomotor Slowing in Older Adults","status":"TERMINATED","sponsor":"New York State Psychiatric Institute","startDate":"2019-01-09","conditions":"Major Depressive Disorder, Dysthymia, Depression","enrollment":51},{"nctId":"NCT04952194","phase":"PHASE4","title":"Clinical Study of Stalevo in the Treatment of Early Parkinson's Disease","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2022-01-01","conditions":"Parkinson Disease","enrollment":180},{"nctId":"NCT04742348","phase":"PHASE4","title":"Research on Translational Outcomes of Alcohol (Project RETRO)","status":"WITHDRAWN","sponsor":"University of Washington","startDate":"2023-02","conditions":"Alcohol Drinking","enrollment":""},{"nctId":"NCT03670953","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of IPX203 in Parkinson's Disease Participants With Motor Fluctuations","status":"COMPLETED","sponsor":"Impax Laboratories, LLC","startDate":"2018-11-06","conditions":"Parkinson's Disease (Disorder)","enrollment":630},{"nctId":"NCT05083260","phase":"PHASE1, PHASE2","title":"NE3107 Activity and Safety in Patients With Parkinson's Disease Using Levodopa","status":"COMPLETED","sponsor":"BioVie Inc.","startDate":"2022-01-04","conditions":"Parkinson Disease","enrollment":46},{"nctId":"NCT04650217","phase":"PHASE4","title":"Levodopa and Exercise for Older Adults With Depression and Psychomotor Slowing","status":"TERMINATED","sponsor":"New York State Psychiatric Institute","startDate":"2021-10-07","conditions":"Depressive Disorder","enrollment":1},{"nctId":"NCT04500106","phase":"","title":"Study to Assess Participant/Caregiver/Investigator Satisfaction of Video-Assisted Telenursing in Adult Participants With Parkinson's Disease Treated With Levodopa-Carbidopa Intestinal Gel","status":"COMPLETED","sponsor":"AbbVie","startDate":"2021-04-22","conditions":"Parkinson's Disease","enrollment":41},{"nctId":"NCT00660673","phase":"PHASE3","title":"Open Label Continuation Treatment Study With Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson's Disease","status":"COMPLETED","sponsor":"AbbVie","startDate":"2009-11-13","conditions":"Advanced Parkinson's Disease","enrollment":262},{"nctId":"NCT04380142","phase":"PHASE3","title":"Study Comparing Continuous Subcutaneous Infusion Of ABBV-951 With Oral Carbidopa/Levodopa Tablets For Treatment Of Motor Fluctuations In Adult Participants With Advanced Parkinson's Disease","status":"COMPLETED","sponsor":"AbbVie","startDate":"2020-10-19","conditions":"Parkinson's Disease (PD)","enrollment":174},{"nctId":"NCT04000919","phase":"PHASE2, PHASE3","title":"Effects of 5HTP and LDOPA on CNS Excitability After SCI","status":"SUSPENDED","sponsor":"Jessica M D'Amico","startDate":"2019-06-19","conditions":"Spinal Cord Injuries","enrollment":30},{"nctId":"NCT03205956","phase":"PHASE1","title":"Measuring Parkinson's Disease Progression","status":"COMPLETED","sponsor":"Kevin J. Black, MD","startDate":"2017-10-19","conditions":"Parkinson's Disease","enrollment":31},{"nctId":"NCT02513485","phase":"PHASE4","title":"Inflammation-related Alterations in Neurocircuitry: Reversal With Levodopa","status":"COMPLETED","sponsor":"Emory University","startDate":"2015-10-09","conditions":"Depression","enrollment":57},{"nctId":"NCT03929068","phase":"PHASE1","title":"Sinemet for Spasticity and Function in Amyotrophic Lateral Sclerosis and Primary Lateral Sclerosis","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2019-05-13","conditions":"Amyotrophic Lateral Sclerosis, Motor Neuron Disease","enrollment":15},{"nctId":"NCT03007888","phase":"PHASE2","title":"A Study to Assess the PK and Pharmacodynamics of IPX203 in Subjects With Advanced Parkinson's Disease","status":"COMPLETED","sponsor":"Impax Laboratories, LLC","startDate":"2016-11-14","conditions":"Advanced Parkinson's Disease","enrollment":28},{"nctId":"NCT05250141","phase":"PHASE1","title":"Bioavailability of Levodopa 250 mg and Carbidopa 25 mg With Regards to Reference Product","status":"COMPLETED","sponsor":"Laboratorios Andromaco S.A.","startDate":"2022-02-14","conditions":"Bioequivalence","enrollment":44},{"nctId":"NCT02346630","phase":"PHASE4","title":"Combining Robotic-Assisted Therapy and Pharmacotherapy in Post-Stroke Rehabilitation","status":"WITHDRAWN","sponsor":"Ross D. Zafonte, MD","startDate":"2015-03","conditions":"Stroke","enrollment":""},{"nctId":"NCT02611713","phase":"","title":"Observational Study Evaluating Long-Term Effectiveness of Duodopa/Duopa in Patients With Advanced Parkinson's Disease","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-01-04","conditions":"Advanced Parkinson's Disease","enrollment":213},{"nctId":"NCT05128175","phase":"PHASE1","title":"Comparative Bioavailability Study of Carbidopa/Levodopa Extended-Release Tablets Under Fasting and Fed Conditions","status":"UNKNOWN","sponsor":"Shanghai WD Pharmaceutical Co., Ltd.","startDate":"2021-10-29","conditions":"Parkinson Disease","enrollment":15},{"nctId":"NCT05036473","phase":"PHASE2","title":"A Study of the Efficacy and Safety of Carbidopa-Levodopa Extended-Release Tablets in Patients With Parkinson's Disease","status":"UNKNOWN","sponsor":"Shanghai WD Pharmaceutical Co., Ltd.","startDate":"2021-10-12","conditions":"Parkinson Disease","enrollment":40},{"nctId":"NCT04441697","phase":"","title":"Sleepiness in Parkinson's Patients With Continuous Dopaminergic Delivery Device or Deep Brain Stimulation","status":"UNKNOWN","sponsor":"Central Hospital, Nancy, France","startDate":"2020-06-01","conditions":"Parkinson Disease","enrollment":30},{"nctId":"NCT01736176","phase":"PHASE3","title":"A Study to Assess the Safety and Efficacy of Levodopa-carbidopa Intestinal Gel (LCIG) for the Treatment of Non-motor Symptoms in Patients With Advanced Parkinson's Disease","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2013-03","conditions":"Advanced Parkinson's Disease","enrollment":39},{"nctId":"NCT02082249","phase":"PHASE3","title":"An Extension Study to Assess the Safety, Tolerability and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease and Persistent Motor-Complications Despite Optimized Treatment With Available Anti-Parkinsonian Medications","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-03-10","conditions":"Advanced Parkinson's Disease","enrollment":30},{"nctId":"NCT00914602","phase":"PHASE1, PHASE2","title":"An Exploratory Study of XP21279 (With Lodosyn®) and Sinemet® in Parkinson's Disease Subjects","status":"COMPLETED","sponsor":"XenoPort, Inc.","startDate":"2009-05","conditions":"Parkinson's Disease","enrollment":14},{"nctId":"NCT01951105","phase":"PHASE4","title":"Effect of L-dopa In Subacute Back Pain Population","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2015-02-24","conditions":"Sub-acute Back Pain","enrollment":72},{"nctId":"NCT01683253","phase":"PHASE4","title":"Remission of ICD by Switching Dopamine Agonist to Levodopa/Carbidopa","status":"COMPLETED","sponsor":"Sandoz","startDate":"2012-11","conditions":"Impulse Control Disorder","enrollment":150},{"nctId":"NCT01171313","phase":"PHASE2","title":"A Efficacy, Safety and Pharmacokinetic Study of XP21279 and Sinemet® in Parkinson's Disease Subjects","status":"COMPLETED","sponsor":"XenoPort, Inc.","startDate":"2010-07","conditions":"Parkinson's Disease","enrollment":35},{"nctId":"NCT02381444","phase":"","title":"Health Related Quality of Life in LCIG Patients and LCIG Eligible Patients Continuing Oral Therapy","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-04-17","conditions":"Parkinson's Disease (PD)","enrollment":136},{"nctId":"NCT03419806","phase":"PHASE1","title":"Study Comparing Intravenous and Subcutaneous Infudopa With Intestinal Duodopa in Patients With Parkinson's Disease","status":"COMPLETED","sponsor":"Vastra Gotaland Region","startDate":"2018-02-16","conditions":"Parkinson Disease","enrollment":25},{"nctId":"NCT02799381","phase":"PHASE3","title":"A Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects With Advanced Parkinson's Disease (DYSCOVER)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-02-09","conditions":"Parkinson's Disease (PD)","enrollment":63},{"nctId":"NCT04082715","phase":"PHASE2","title":"Transition From Acute to Chronic Back Pain : Effect of L-dopa,Gender,and Associated Brain Plasticity","status":"WITHDRAWN","sponsor":"Second Affiliated Hospital of Wenzhou Medical University","startDate":"2019-10","conditions":"Chronic Back Pain","enrollment":""},{"nctId":"NCT03362879","phase":"","title":"COmedication Study Assessing Mono- and cOmbination Therapy With Levodopa-carbidopa inteStinal Gel","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-12-14","conditions":"Parkinson's Disease (PD)","enrollment":412},{"nctId":"NCT02782481","phase":"PHASE3","title":"A Clinical Study Investigating the Efficacy, Tolerability, and Safety of Continuous Subcutaneous ND0612 Infusion Given as Adjunct Treatment to Oral Levodopa in Patients With Parkinson's Disease With Motor Fluctuations","status":"WITHDRAWN","sponsor":"NeuroDerm Ltd.","startDate":"2016-08","conditions":"Parkinson's Disease","enrollment":""},{"nctId":"NCT02386475","phase":"PHASE4","title":"Effect of Serotonin and Levodopa in Ischemic Stroke","status":"COMPLETED","sponsor":"Hospital de Granollers","startDate":"2015-01","conditions":"Stroke","enrollment":39},{"nctId":"NCT01096186","phase":"PHASE3","title":"An Open Label Extension Study of the Safety and Clinical Utility of IPX066 in Subjects With Parkinson's Disease","status":"COMPLETED","sponsor":"Impax Laboratories, LLC","startDate":"2010-03","conditions":"Parkinson's Disease","enrollment":617},{"nctId":"NCT01411137","phase":"PHASE3","title":"Carbidopa-Levodopa (CD-LD) ER Alone or in Combination With CD-LD IR to IPX066 Followed by IPX066 Extension Safety Study","status":"COMPLETED","sponsor":"Impax Laboratories, LLC","startDate":"2011-08","conditions":"Parkinson's Disease","enrollment":43},{"nctId":"NCT02271503","phase":"PHASE2","title":"A Study to Assess the PK and Pharmacodynamics of IPX203 in Patients With Advanced Parkinson's Disease","status":"COMPLETED","sponsor":"Impax Laboratories, LLC","startDate":"2015-11","conditions":"Parkinson's Disease","enrollment":26},{"nctId":"NCT00880620","phase":"PHASE3","title":"A Study To Evaluate The Safety And Efficacy Of IPX066 In Subjects With Parkinson's Disease","status":"COMPLETED","sponsor":"Impax Laboratories, LLC","startDate":"2009-04","conditions":"Parkinson's Disease","enrollment":381},{"nctId":"NCT00279825","phase":"PHASE2","title":"Comparison of IPX054, IR Carbidopa-Levodopa, and CR Carbidopa-Levodopa in Subjects With Parkinson's Disease","status":"COMPLETED","sponsor":"Impax Laboratories, LLC","startDate":"2006-01","conditions":"Idiopathic Parkinson's Disease","enrollment":16},{"nctId":"NCT00253084","phase":"PHASE2","title":"Comparison of IPX054 and Immediate-Release Carbidopa-Levodopa in Patients With Parkinson's Disease","status":"COMPLETED","sponsor":"Impax Laboratories, LLC","startDate":"2005-11","conditions":"Parkinson's Disease","enrollment":12},{"nctId":"NCT02706977","phase":"PHASE1","title":"The Effect of Dopamine on Diabetic Retinopathy","status":"COMPLETED","sponsor":"Emory University","startDate":"2016-01","conditions":"Diabetes","enrollment":60},{"nctId":"NCT03918616","phase":"","title":"P2X7 Receptor, Inflammation and Neurodegenerative Diseases","status":"COMPLETED","sponsor":"University of Pisa","startDate":"2017-02-20","conditions":"Neuro-Degenerative Disease","enrollment":50},{"nctId":"NCT02605434","phase":"PHASE3","title":"A Study to Assess the Safety and Efficacy of the of the Gastric-retentive AP-CD/LD in Advanced Parkinson's Patients","status":"UNKNOWN","sponsor":"Intec Pharma Ltd.","startDate":"2016-03","conditions":"Parkinson's Disease","enrollment":420},{"nctId":"NCT03887884","phase":"PHASE1","title":"Pharmacokinetic Study of CVT-301 (Levodopa Inhalation Powder)","status":"COMPLETED","sponsor":"Acorda Therapeutics","startDate":"2019-03-05","conditions":"Parkinson's Disease","enrollment":23},{"nctId":"NCT03665454","phase":"PHASE1","title":"PF 06412562 in Subjects With Advanced Stage Parkinson's Disease","status":"COMPLETED","sponsor":"Milton S. Hershey Medical Center","startDate":"2018-09-24","conditions":"Parkinson Disease","enrollment":8},{"nctId":"NCT03591757","phase":"EARLY_PHASE1","title":"Short-term Effects of TOLCAPONE on Transthyretin Stability in Subjects With Leptomeningeal TTR Amyloidosis (ATTR)","status":"COMPLETED","sponsor":"Boston University","startDate":"2018-10-30","conditions":"Transthyretin Amyloidosis, Amyloidosis, Leptomeningeal, Transthyretin-Related","enrollment":10},{"nctId":"NCT02873351","phase":"PHASE2","title":"A Safety and Efficacy Study of Carbidopa-levodopa in Patients With Macular Degeneration","status":"WITHDRAWN","sponsor":"Snyder, Robert W., M.D., Ph.D., P.C.","startDate":"2019-09","conditions":"Age-related Macular Degeneration","enrollment":""},{"nctId":"NCT03496870","phase":"PHASE1","title":"A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of Opicapone in Subjects With Parkinson's Disease Taking Levodopa.","status":"COMPLETED","sponsor":"Neurocrine Biosciences","startDate":"2018-02-08","conditions":"Parkinson Disease","enrollment":16},{"nctId":"NCT02289729","phase":"","title":"Patient- and Caregiver-reported Symptoms and Outcomes With Levodopa/Carbidopa Intestinal Gel for the Treatment of Advanced Parkinson's Disease","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-10","conditions":"Parkinson's Disease","enrollment":62},{"nctId":"NCT03793491","phase":"","title":"Personality, as a Predictive Factor of Therapeutic Response on Quality of Life After Continuous Perfusion of Dopaminergic Drugs, in Parkinson's Disease","status":"UNKNOWN","sponsor":"University Hospital, Toulouse","startDate":"2018-12-18","conditions":"Parkinson Disease","enrollment":60},{"nctId":"NCT03462043","phase":"PHASE3","title":"A Study in Patients With Advanced Parkinson's Disease to Assess the Relative Bioavailability of Levodopa Administered as ND0612 Subcutaneous Infusion Versus Levodopa Administered as Carbidopa-Levodopa Enteral Suspension","status":"WITHDRAWN","sponsor":"NeuroDerm Ltd.","startDate":"2018-04-10","conditions":"Parkinson","enrollment":""},{"nctId":"NCT01754129","phase":"","title":"Global REsponsE During iNFusIon of a gEl With LevoDopa/Carbidopa","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2012-12","conditions":"Parkinson's Disease","enrollment":148}],"_emaApprovals":[],"_faersSignals":[{"count":37,"reaction":"DRUG INTERACTION"},{"count":30,"reaction":"PARKINSON^S DISEASE"},{"count":21,"reaction":"DYSKINESIA"},{"count":19,"reaction":"VOMITING"},{"count":18,"reaction":"DRUG INEFFECTIVE"},{"count":17,"reaction":"TREMOR"},{"count":16,"reaction":"DYSPNOEA"},{"count":16,"reaction":"MALAISE"},{"count":14,"reaction":"DYSPHAGIA"},{"count":14,"reaction":"MUSCULOSKELETAL STIFFNESS"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["sinemet group"],"phase":"marketed","status":"active","brandName":"sinemet plus","genericName":"sinemet plus","companyName":"Hospital de Granollers","companyId":"hospital-de-granollers","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sinemet Plus combines levodopa (a dopamine precursor) with carbidopa (a decarboxylase inhibitor) and entacapone (a COMT inhibitor) to increase dopamine availability in the brain for Parkinson's disease treatment. Used for Parkinson's disease with motor fluctuations.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}